ICD G71.02ORPHA:269FSHD

Facioscapulohumeral Muscular Dystrophy

Facioscapulohumeral muscular dystrophy (FSHD) is the third most common muscular dystrophy, causing progressive weakness of the face, shoulders, and upper arms. It is caused by aberrant DUX4 gene expression. Severity varies greatly. Clinical trials targeting DUX4 are in progress and represent significant therapeutic hope.

555
Articles
74
Trials (6 AU)
Updated
26 March 2026
Loading...

Common Questions

What is Facioscapulohumeral Muscular Dystrophy?

Facioscapulohumeral muscular dystrophy (FSHD) is the third most common muscular dystrophy, causing progressive weakness of the face, shoulders, and upper arms. It is caused by aberrant DUX4 gene expression. Severity varies greatly. Clinical trials targeting DUX4 are in progress and represent significant therapeutic hope.

How many clinical trials are available for Facioscapulohumeral Muscular Dystrophy?

RareWays currently indexes 74 clinical trials for Facioscapulohumeral Muscular Dystrophy, of which 22 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.

Where does the research data for Facioscapulohumeral Muscular Dystrophy come from?

RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.

Get research updates

Monthly email when new findings are published for Facioscapulohumeral Muscular Dystrophy.

No spam. Unsubscribe any time. Not medical advice.

This information is for general awareness only.

For guidance specific to your situation, please speak with your healthcare team.